Quest Diagnostics to Offer FDA-Cleared Fujirebio Blood Test for Alzheimer’s Disease

Key Takeaways:

• Quest Diagnostics to Offer FDA-Cleared Alzheimer’s Test
• Test Available for Use This Summer
• Expansion of AD-Detect™ Product Line
• Developed by Fujirebio
• Advancement in Assessing Symptomatic Patients

Quest Diagnostics Introduces FDA-Cleared Alzheimer’s Blood Test

Building on Its Pioneering AD-Detect™ Product Line

Quest Diagnostics has announced it will offer an FDA-cleared blood test for Alzheimer’s disease developed by Fujirebio. The test is slated to be available for clinical and research use as soon as this summer, marking a significant development in the assessment of symptomatic patients.

Expanding the AD-Detect™ Product Line

This new offering builds upon Quest Diagnostics’ pioneering AD-Detect™ product line, which has been instrumental in providing healthcare professionals with tools to assess Alzheimer’s disease symptoms. The addition of the FDA-cleared test enhances the company’s commitment to advancing diagnostic options for neurodegenerative conditions.

Developed by Fujirebio

The blood test, developed by Fujirebio, has received clearance from the U.S. Food and Drug Administration (FDA). By incorporating Fujirebio’s innovative technology, Quest Diagnostics aims to improve the accuracy and accessibility of Alzheimer’s disease diagnostics.

Available for Clinical and Research Use This Summer

Set to be available as soon as this summer, the test will serve both clinical practices and research initiatives. Its availability underscores the urgency in addressing Alzheimer’s disease, which affects millions of individuals globally and presents significant challenges in diagnosis and treatment.

Advancing Patient Assessment

The introduction of this FDA-cleared blood test represents a substantial advancement in assessing patients exhibiting symptoms of Alzheimer’s disease. It offers a less invasive and potentially more accessible option compared to traditional diagnostic methods, facilitating earlier intervention and management.

With the launch of the Fujirebio-developed test, Quest Diagnostics continues to lead in providing innovative diagnostic solutions. This development not only expands their AD-Detect™ product line but also reinforces their dedication to enhancing patient care in the realm of neurodegenerative diseases.